Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 19/20 | 0.42 |
| ▸ | CTSD | P07339 | 5/20 | 0.41 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18379122 | 0.89 | TDP1 (0.38) | BACE1CTSDBACE2APPCYP2D6 | |
| SCHEMBL18496845 | 0.86 | BACE1 (0.42) | BACE1CTSDBACE2APPCYP2D6 | |
| SCHEMBL16461418 | 0.86 | BACE1 (0.46) | BACE1CTSDBACE2APPCYP2D6 | |
| SCHEMBL27659789 | 0.85 | ALDH1A1 (0.45) | — | |
| SCHEMBL18698889 | 0.84 | BACE1 (0.42) | BACE1CTSDBACE2APPCYP2D6 | |
| SCHEMBL15910444 | 0.83 | BACE1 (0.46) | BACE1CTSDBACE2APPCYP2D6 | |
| SCHEMBL10328693 | 0.82 | KMT2A (0.38) | BACE1CTSDBACE2APPCYP2D6 | |
| SCHEMBL362634 | 0.81 | KMT2A (0.46) | BACE1BACE2APPCYP2D6 | |
| SCHEMBL15933976 | 0.80 | BACE1 (0.46) | BACE1CTSDBACE2APPCYP2D6 | |
| SCHEMBL312811 | 0.80 | TSHR (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 205 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103403001-B | Heterocyclic derivatives and their use in the treatment of neurological disorders | 诺瓦提斯公司 | 2016-08-17 | — | — | CN | claimed |
| EP-2663561-B1 | NOVEL HETEROCYCLIC DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2016-03-16 | — | — | EP | claimed |
| US-20150322038-A1 | PYRAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2015-11-12 | — | — | US | claimed |
| US-20150203481-A1 | Novel Heterocyclic Derivatives and Their Use in the Treatment of Neurological Disorders | NOVARTIS AG (CH) | 2015-07-23 | — | — | US | claimed |
| EP-2663559-B1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2015-07-01 | — | — | EP | claimed |
| CN-102712621-B | Pyrazine derivatives and their use in the treatment of neurological disorders | NOVARTIS AG | 2015-03-11 | — | — | CN | claimed |
| EP-2456763-B1 | OXAZINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2015-01-21 | — | — | EP | claimed |
| US-20150018338-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2015-01-15 | — | — | US | claimed |
| US-8865712-B2 | Heterocyclic derivatives and their use in the treatment of neurological disorders | NOVARTIS AG (CH) | 2014-10-21 | — | — | US | claimed |
| CN-102471293-B | Oxazine derivatives and their use as BACE inhibitors for the treatment of neurological disorders | NOVARTIS AG (CH) | 2014-10-01 | — | — | CN | claimed |
| US-20120277244-A1 | PYRAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2012-11-01 | — | — | US | claimed |
| CN-102712621-A | Pyrazine derivatives and their use in the treatment of neurological disorders | NOVARTIS AG | 2012-10-03 | — | — | CN | claimed |
| CN-102666507-A | Oxazine derivatives and their use in the treatment of neurological disorders | NOVARTIS AG | 2012-09-12 | — | — | CN | claimed |
| EP-2483255-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | Novartis AG (CH) | 2012-08-08 | — | — | EP | claimed |
| US-20120184539-A1 | Novel Heterocyclic Derivatives and Their Use in the Treatment of Neurological Disorders | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2012-07-19 | — | — | US | claimed |
| WO-2012095469-A1 | NOVEL HETEROCYCLIC DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2012-07-19 | — | — | WO | claimed |
| WO-2012095521-A1 | BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | NOVARTIS AG (CH) | 2012-07-19 | — | — | WO | claimed |
| WO-2012095463-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2012-07-19 | — | — | WO | claimed |
| CN-102471293-A | Oxazine derivatives and their use as BACE inhibitors for the treatment of neurological disorders | NOVARTIS AG | 2012-05-23 | — | — | CN | claimed |
| WO-2012006953-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2012-01-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322038-A1 | PYRAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | GRIK5, GRIN2C, GRIN2A | BACE1 436/4885CTSD 3072/4885BACE2 736/4885 |
| US-20150203481-A1 | Novel Heterocyclic Derivatives and Their Use in the Treatment of Neurological Disorders | BACE2, BACE1, PSEN2 | BACE1 2/4885CTSD 106/4885BACE2 1/4885 |
| US-20120277244-A1 | PYRAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | GRIK5, GRIN2C, GRIN2A | BACE1 353/4885CTSD 3407/4885BACE2 734/4885 |
| US-20150018338-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | OTC, GRIK5, GRIN2C | BACE1 69/4885CTSD 3279/4885BACE2 161/4885 |
| US-20120184539-A1 | Novel Heterocyclic Derivatives and Their Use in the Treatment of Neurological Disorders | BACE2, BACE1, PSEN2 | BACE1 2/4885CTSD 106/4885BACE2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.